Cost-effectiveness of a quality improvement programme to reduce central line-associated bloodstream infections in intensive care units in the USA

BMJ Open

Volumn 4, Issue 9, 2014, Pages

  Herzer, Kurt R ^a   Niessen, Louis ^b   Constenla, Dagna O ^c   Ward, William J ^c   Pronovost, Peter J ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CATHETER INFECTION; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION TREE; HUMAN; INFECTION CONTROL; INTENSIVE CARE UNIT; INVESTMENT; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; OUTCOME ASSESSMENT; SENSITIVITY ANALYSIS; TOTAL QUALITY MANAGEMENT; UNITED STATES; ADVERSE EFFECTS; CATHETER-RELATED INFECTIONS; CENTRAL VENOUS CATHETERIZATION; COST BENEFIT ANALYSIS; ECONOMICS; EPIDEMIOLOGY; HEALTH CARE COST; PROGRAM EVALUATION; STANDARDS; STATISTICS AND NUMERICAL DATA;

CATHETER-RELATED INFECTIONS; CATHETERIZATION, CENTRAL VENOUS; COST-BENEFIT ANALYSIS; DECISION TREES; HEALTH CARE COSTS; HUMANS; INTENSIVE CARE UNITS; PROGRAM EVALUATION; QUALITY IMPROVEMENT; UNITED STATES;

EID: 84907434564     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006065     Document Type: Article

References (46)

1. Mermel LA. Prevention of intravascular catheter-related infections. Ann Intern Med 2000;132:391-402.
2. Burke JP. Infection control - a problem for patient safety. N Engl J Med 2003;348:651-6.
3. Klevens RM, Edwards JR, Richards CL Jr, et al. Estimating health care-associated infections and deaths in U.S. hospitals, 2002. Public Health Rep 2007;122:160-6.
4. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Infect Control Hosp Epidemiol 2002;23:759-69.
5. Digiovine B, Chenoweth C, Watts C, et al. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med 1999;160:976-81.
6. Pittet D, Tarara D, Wenzel RP. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994;271:1598-601.
7. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006;355:2725-32.
8. Berenholtz SM, Pronovost PJ, Lipsett PA, et al. Eliminating catheter-related bloodstream infections in the intensive care unit. Crit Care Med 2004;32:2014-20.
9. Berenholtz SM, Pham JC, Thompson DA, et al. Collaborative cohort study of an intervention to reduce ventilator-associated pneumonia in the intensive care unit. Infect Control Hosp Epidemiol 2011;32:305-14.
10. Lin DM, Weeks K, Bauer L, et al. Eradicating central line-associated bloodstream infections statewide: the Hawaii experience. Am J Med Qual 2012;27:124-9.
11. Lipitz-Snyderman A, Steinwachs D, Needham DM, et al. Impact of a statewide intensive care unit quality improvement initiative on hospital mortality and length of stay: retrospective comparative analysis. BMJ 2011;342:d219.
12. Bion J, Richardson A, Hibbert P, et al. 'Matching Michigan': a 2-year stepped interventional programme to minimise central venous catheter-blood stream infections in intensive care units in England. BMJ Qual Saf 2013;22:110-23.
13. Marsteller JA, Sexton JB, Hsu YJ, et al. A multicenter, phased, cluster-randomized controlled trial to reduce central line-associated bloodstream infections in intensive care units. Crit Care Med 2012;40:2933-9.
14. Niessen LW, Grijseels EW, Rutten FF. The evidence-based approach in health policy and health care delivery. Soc Sci Med 2000;51:859-69.
15. Grimshaw JM, Thomas RE, MacLennan G, et al. Effectiveness and efficiency of guideline dissemination and implementation strategies. Health Technol Assess 2004;8:iii-iv, 1-72.
16. Hoomans T, Evers SM, Ament AJ, et al. The methodological quality of economic evaluations of guideline implementation into clinical practice: a systematic review of empiric studies. Value Health 2007;10:305-16.
17. Graves N, Harbarth S, Beyersmann J, et al. Estimating the cost of health care-associated infections: mind your p's and q's. Clin Infect Dis 2010;50:1017-21.
18. Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA 1999;282: 554-60.
19. Halton KA, Cook DA, Whitby M, et al. Cost effectiveness of antimicrobial catheters in the intensive care unit: addressing uncertainty in the decision. Crit Care 2009;13:R35.
20. Needham DM, Scales DC, Laupacis A, et al. A systematic review of the Charlson comorbidity index using Canadian administrative databases: a perspective on risk adjustment in critical care research. J Crit Care 2005;20:12-19.
21. Pronovost PJ, Berenholtz SM, Goeschel C, et al. Improving patient safety in intensive care units in Michigan. J Crit Care 2008;23:207-21.
22. Pronovost PJ, Berenholtz SM, Needham DM. Translating evidence into practice: a model for large scale knowledge translation. BMJ 2008;337:a1714.
23. Fletcher S. Catheter-related bloodstream infection. Contin Educ Anaesth Crit Care Pain 2005;5:49-51.
24. Brun-Buisson C. New technologies and infection control practices to prevent intravascular catheter-related infections. Am J Respir Crit Care Med 2001;164:1557-8.
25. Veenstra DL, Saint S, Saha S, et al. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA 1999;281:261-7.
26. Martin MA, Pfaller MA, Wenzel RP. Coagulase-negative staphylococcal bacteremia. Mortality and hospital stay. Ann Intern Med 1989;110:9-16.
27. Smith RL, Meixler SM, Simberkoff MS. Excess mortality in critically ill patients with nosocomial bloodstream infections. Chest 1991;100:164-7.
28. Arnow PM, Quimosing EM, Beach M. Consequences of intravascular catheter sepsis. Clin Infect Dis 1993;16:778-84.
29. Waters HR, Korn R Jr, Colantuoni E, et al The business case for quality: economic analysis of the Michigan Keystone Patient Safety Program in ICUs. Am J Med Qual 2011;26:333-9.
30. Graves N, Weinhold D, Tong E, et al. Effect of healthcare-acquired infection on length of hospital stay and cost. Infect Control Hosp Epidemiol 2007;28:280-92.
31. Graves N. Economics and preventing hospital-acquired infection. Emerg Infect Dis 2004;10:561-6.
32. Society of Critical Care Medicine. Compensation of critical care professionals. Society of Critical Care Medicine, 2009.
33. Warren DK, Quadir WW, Hollenbeak CS, et al. Attributable cost of catheter-associated bloodstream infections among intensive care patients in a nonteaching hospital. Crit Care Med 2006;34:2084-9.
34. American Hospital Association. AHA Hospital Statistics. 2013 ed. American Hospital Association, 2012.
35. Pronovost PJ, Goeschel CA, Colantuoni E, et al. Sustaining reductions in catheter related bloodstream infections in Michigan intensive care units: observational study. BMJ 2010;340:c309.
36. Leatherman S, Berwick D, Iles D, et al. The business case for quality: case studies and an analysis. Health Aff (Millwood) 2003;22:17-30.
37. Galvin RS, Delbanco S, Milstein A, et al. Has the leapfrog group had an impact on the health care market? Health Aff (Millwood) 2005;24:228-33.
38. Hsu E, Lin D, Evans SJ, et al. Doing well by doing good: assessing the cost savings of an intervention to reduce central line-associated bloodstream infections in a Hawaii hospital. Am J Med Qual 2014;29:13-19.
39. Halton K, Graves N. Economic evaluation and catheter-related bloodstream infections. Emerg Infect Dis 2007;13:815-23.
40. Dimick JB, Pronovost PJ, Heitmiller RF, et al. Intensive care unit physician staffing is associated with decreased length of stay, hospital cost, and complications after esophageal resection. Crit Care Med 2001;29:753-8.
41. Grutters JP, Sculpher M, Briggs AH, et al. Acknowledging patient heterogeneity in economic evaluation : a systematic literature review. Pharmacoeconomics 2013;31:111-23.
42. Niel-Weise BS, Stijnen T, van den Broek PJ. Anti-infective-treated central venous catheters: a systematic review of randomized controlled trials. Intensive Care Med 2007;33:2058-68.
43. Hockenhull JC, Dwan K, Boland A, et al. The clinical effectiveness and cost-effectiveness of central venous catheters treated with anti-infective agents in preventing bloodstream infections: a systematic review and economic evaluation. Health Technol Assess 2008;12:iii-iv, xi-xii, 1-154.
44. Centers for Disease Control and Prevention. National and State Healthcare Association Infections Progress Report. Atlanta, 2014.
45. Wise ME, Scott RD II, Baggs JM, et al. National estimates of central line-associated bloodstream infections in critical care patients. Infect Control Hosp Epidemiol 2013;34:547-54.
46. Dick A, Liu H, Zwanziger J, et al. Long-term survival and healthcare utilization outcomes attributable to sepsis and pneumonia. BMC Health Serv Res 2012;12:432.